Commentary on ''Microbial spectrum and primary resistance to rifampicin in infectious complications in vascular surgery: limits to the use of rifampicin-bonded prosthetic grafts''.
Naylor
A Ross
AR
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D001807:Blood Vessel Prosthesis / Q000382:microbiology*; D020099:Coated Materials, Biocompatible; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology*; D012086:Reoperation; D012189:Retrospective Studies; D012293:Rifampin / Q000008:administration & dosage*; D055502:Secondary Prevention
D000904:Antibiotics, Antitubercular; D020099:Coated Materials, Biocompatible; D012293:Rifampin